Opendata, web and dolomites

BrEXo-Apt TERMINATED

Non-invasive and accurate diagnosis and treatment of breast cancer.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BrEXo-Apt project word cloud

Explore the words cloud of the BrEXo-Apt project. It provides you a very rough idea of what is the project "BrEXo-Apt" about.

therapy    compounds    healthy    tissues    progression    released    diagnosis    screening    evidences    acids    aptamers    treatment    therapeutic    exosomes    blood    glioma    innovative    mainly    extracellular    detection    plasmapheresis    rnas    platforms    earliest    angiogenesis    cancer    quintavalle    progresses    internalization    affinity    larger    discriminate    play    interfering    attracted    resistance    micrornas    remove    recognize    samples    organs    categories    cells    exosome    indicates    bc    data    activator    sandwich    dr    of    release    precise    indicate    invasive    tumour    drug    prognostic    surrounding    predictive    assay    circulating    antisense    lung    increasing    patients    interesting    patient    escape    dnas    instrumental    overcome    interfere    generate    metastasis    spreading    surveillance    aptamer    types    preliminary    biomarkers    tests    nucleic    mda231    strategy    invasion    immune    diagnostic    block    inhibition    breast   

Project "BrEXo-Apt" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 187˙572 €
 EC max contribution 187˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 187˙572.00

Map

 Project objective

Increasing evidences indicate that the release of a great numbers of exosomes by tumour cells play a key role in tumour progression, drug resistance, immune surveillance escape, angiogenesis, tumour invasion and metastasis. For this reason, cancer-derived exosomes are emerging as very interesting targets for cancer therapy and diagnosis. In particular, extracellular exosomes may have great potential as early diagnostic and prognostic biomarkers for many types of cancer, including breast cancer. Early screening methods for breast cancer are mainly based on instrumental tests, that may cause in many cases a failure to reach particular categories of patients. This failure could be overcome with the availability of specific and predictive circulating biomarkers allowing non-invasive earliest tumour detection on a larger scale of patients. Indeed, progresses in developing nucleic acids-based therapeutic compounds, including antisense DNAs, aptamers, short interfering/microRNAs, and short activator RNAs, have attracted great interest as emerging platforms for precise cancer treatment. Dr Quintavalle has identified aptamers that specifically recognize BC-released exosomes and are able to discriminate between breast cancer derived exosome and glioma or lung cancer derived exosomes. Preliminary data indicates also that these aptamers are able to block the internalization of MDA231 derived exosome on MDA231 cells. To develop a new diagnostic and therapeutic strategy, Dr Quintavalle will aim to exploit the identified aptamers to design an innovative aptamer-based sandwich assay for their specific detection in patient blood samples. Moreover, since the inhibition of cancer exosome uptake by surrounding healthy tissues and organs would represent an effective strategy to interfere with tumour spreading and development, Dr. Quintavalle will aim to generate an affinity plasmapheresis system by using BC specific aptamers for specifically remove BC-derived exosome from patient blood.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREXO-APT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREXO-APT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

RESTRICTIONAPP (2019)

A multilinear approach to the restriction problem with applications to geometric measure theory, the Schrödinger equation and inverse problems

Read More